McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in September:
- 12th Annual Wells Fargo Securities Healthcare Conference in Boston on Wednesday, September 6, 2017 at 10:50 a.m. Eastern Time (ET);
- Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 13, 2017 at 11:40 a.m. ET; and
- Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017 at 1:05 p.m. ET.
The presentations will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in two ongoing Phase 2a studies in patients with idiopathic pulmonary fibrosis. To learn more, please visit: www.globalbloodtx.com and follow the company on Twitter: @GBT_News.
Contact Information: Myesha Lacy (investors) GBT 650-351-4730 [email protected] Julie Normart (media) Pure Communications 415-946-1087 [email protected]
